Authors
Stéphanie G Trouche-Sabatier, Brigitte Trétarre, Thibaut Murez, Nicolas Abdo, Grégoire Poinas, Anne-Sophie Foucan, François Iborra
Published in
The French journal of urology. Pages 103180. Aug 14, 2026. Epub Aug 14, 2026.
Abstract
In older men, non-metastatic prostate cancer (NMPC) may be under or overtreated, and curative treatments are rarely achieved.
The aim of this study was to analyze the primo-management and survival of non-metastatic prostate cancers in subjects aged 75 and over in a French department.
We used retrospective, population-based data to identify subjects aged 75 and over at diagnosis with NMPC between 1 January 2017 and 31 December 2020. Patients were divided into 2 groups: group 1, patients aged 75 to 79 years, and group 2, patients aged 80 years and over.
We included 1077 patients, 606 in group 1 and 471 in group 2. Of the 794 patients diagnosed on prostate biopsies, 73.7% in group 1 and 35.1% in group 2 received a local curative treatment (p<0.001). Of the 219 NMPC patients diagnosed for a benign prostate hypertrophy (BPH), 73% in group 1 and 69.5% in group 2 were placed on WW after diagnosis and 13.5% in group 1 and 3.7% in group 2 had an active surveillance. Men in group 2 were more frequently put on androgen deprivation therapy (21.3% vs. 5.4%).
Patients aged 80 and over received fewer local curative treatments, and hormone therapy was overused. In our study, patients with a local curative treatment strategy had a better survival in both age groups. Treatment decisions for these patients should not be based on chronological age, but on cancer prognosis and life expectancy.
PMID:
42600849
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0